XC7 / NP Therap - LARVOL DELTA

Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Completed; Sponsor: NP Therapeutics; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease

Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Active, not recruiting; Sponsor: NP Therapeutics; Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 in Healthy Volunteers (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: NP Therapeutics

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease